• American Journal of Sports Medicine to publish results of an FDA-approved clinical trial for treating knee pain

  Posted on: 09 March, 2020

  Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees. GID BIO announced the acceptance by the American Journal of Sports Medicine to publish results next month of an FDA-approved multi-site, randomized, placebo-controlled Phase IIb clinical trial measuring the safety and efficacy of its SVF-2 device and point-of-care (POC) therapy intended to treat pain and function associated with knee osteoarthritis.

  Read More

• Mesenchymal Stem Cells (MSCs) in the Era of Regenerative Medicine

  Posted on: 09 March, 2020

  Mesenchymal stem cells are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum, a layer of connective tissue that envelops the bones. They are also known as: Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells. Given this naming variability, as well as urging by Dr. Caplan to rename the cells so that patients don’t assume specific medical benefits, these cells are best known as: MSCs.

  Read More

• Tendon Injury in Regenerative Medicine

  Posted on: 18 December, 2019

  Tendinitis is an injury that is the result of overstressing a tendon. This injury can come from doing acute movements such as physical activities that your body is not entirely used to. After a significant initial injury, a tendon may become painful and inflamed for 2 to 3 weeks, and hence the condition is called acute tendonitis. If not appropriately treated with the RICE protocol or NSAIDs, continued overuse can result in repeated tendonitis and lead to chronic degradation of the tendon, called tendinopathy.

  Read More